EGFR and lung adenocarcinoma: Previous studies established erlotinib was superior to gefitinib in advanced EGFR-mutated patients with leptomeningeal metastases from lung adenocarcinomas that progressed during gefitinib therapy but responded to erlotinib [3, 15, 20, 21].